Core Viewpoint - As of January 22, 2026, the disclosure rate of active equity funds' quarterly reports reached 100%, with a slight decrease in overall positions but remaining at historically high levels [2][3] Fund Positioning - Active equity funds' positions decreased by 0.83 percentage points to 86.6%, still the second highest level after Q3 2025, with ordinary stock, mixed equity, and flexible allocation funds decreasing by 0.5, 0.8, and 0.9 percentage points respectively [3] - The ChiNext board saw an increase in positions by 1.2 percentage points to 25.0%, while the Sci-Tech Innovation board decreased by 0.9 percentage points to 16.6%, and the main board decreased by 0.3 percentage points to 58.2% [3] Sector Allocation - The sectors with the highest increases in positions were non-ferrous metals (+2.3 percentage points), communication (+1.9 percentage points), and non-bank financials (+0.9 percentage points), with non-ferrous metals increasing for four consecutive quarters and communication for three [3] - The sectors with the largest decreases were electronics (-1.7 percentage points), pharmaceuticals and biology (-1.5 percentage points), and media (-1.2 percentage points) [3] Sub-sector Insights - In the secondary industry, the sectors with the highest increases were communication equipment (+1.9 percentage points), industrial metals (+1.2 percentage points), and insurance (+0.9 percentage points), while the largest decreases were in consumer electronics (-1.9 percentage points), batteries (-1.3 percentage points), and chemical pharmaceuticals (-1.0 percentage points) [3] Stock Performance - The stocks with the highest increases in positions included Zhongji Xuchuang, Xinyi Technology, Dongshan Precision, China Ping An, and Zijin Mining, while the stocks with the largest decreases included Industrial Fulian, Yiwei Lithium Energy, CATL, Luxshare Precision, and Focus Media [3] Hong Kong Market Overview - In the Hong Kong market, the active equity positions decreased by 3.1 percentage points to 16.0%, with increases in financials, materials, and energy sectors, while decreases were seen in non-essential consumer, information technology, and healthcare sectors [3] - The most increased stocks were China Ping An H, CNOOC H, and China Life H, while the most decreased stocks were Alibaba, Tencent Holdings, and SMIC [3]

（文章来源：证券日报） 本报讯 1月22日晚间，重庆博腾制药科技股份有限公司（以下简称"博腾股份"）发布2025年度业绩预 告，预计归属于上市公司股东的净利润为8000万元至10500万元，同比扭亏为盈。 2025年度，公司坚定围绕"收入恢复增长，逐步实现扭亏为盈"的经营目标，持续加强业务拓展，提升经 营大盘系统管理水平。公告显示，报告期内，公司预计实现营业收入33.5亿元至35亿元，同比增长11% 至16%，收入增长主要由临床三期至商业化阶段的项目需求驱动。盈利增长主要得益于营业收入增长带 来的规模效应、降本增效和精益运营提升毛利率、费用稳中有降等。此外，随着公司业务恢复增长，公 司资产的使用效率逐步提升，基于初步减值测试，公司本期资产减值损失预计将同比大幅减少。 ...

西点药业（301130）(301130.SZ)公告，公司拟回购公司股份用于实施员工持股计划或股权激励。回购 股份的资金总额不低于2500万元(含)，不超过5000万元(含)。回购股份的价格不超过42.00元/股(含)。回 购股份的实施期限自公司董事会审议通过本次回购股份方案之日起12个月内 ...

智通财经APP讯，博腾股份(300363.SZ)披露2025年年度业绩预告，公司预计归属于上市公司股东的净利 润8000万元至1.05亿元，扭亏为盈;归属于上市公司股东的扣除非经常性损益的净利润4800万元至7000 万元。 ...

博腾股份（300363）(300363.SZ)披露2025年年度业绩预告，公司预计归属于上市公司股东的净利润 8000万元至1.05亿元，扭亏为盈;归属于上市公司股东的扣除非经常性损益的净利润4800万元至7000万 元。 ...

南财智讯1月22日电，西点药业公告，公司"草酸艾司西酞普兰原料药生产项目"计划投资5,350.19万元， 资金来源于首次公开发行股票的募集资金，用于原料药生产建设。由于宗地内原有污水管线、高压入户 线及外部化工管线影响施工，导致规划设计、土建建设及设备安装延迟，项目整体进度不及预期，公司 决定将该项目预定可使用状态时间由2026年2月23日延期至2026年6月30日。本次延期不涉及项目实施主 体、建设内容、投资规模及资金用途变更，不会对公司主营业务和整体募资安排造成实质性影响，亦不 改变公司既定战略，有利于提高募集资金使用效率。公司将继续加强项目管理，确保按期完成建设。 ...

1月22日，一品红收跌1.34%，收盘价为35.31元，发生1笔大宗交易，合计成交量11.88万股，成交金额 419.48万元。 责任编辑：小浪快报 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 第1笔成交价格为35.31元，成交11.88万股，成交金额419.48万元，溢价率为0.00%，买方营业部为机构 专用，卖方营业部为中信证券股份有限公司上海分公司。 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为419.48万元。该股近5个交易日累 计下跌9.14%，主力资金合计净流出8981.29万元。 ...

南财智讯1月22日电，西点药业公告，公司于2026年1月22日召开第八届董事会第十四次会议，审议通过 了相关议案，同意使用额度不超过0.75亿元的暂时闲置募集资金（含超募资金）进行现金管理，投资安 全性高、流动性好、期限不超过12个月的保本型投资产品。使用期限自董事会审议通过之日起12个月内 有效，资金在额度范围内可滚动使用。该事项不会影响募集资金投资项目进度和公司正常生产经营。 ...

Group 1 - The core point of the article is that Chengda Pharmaceutical (301201.SZ) is currently experiencing a decline in stock price, with a closing price of 39.67 yuan and a drop of 4.16%, indicating that the stock is in a state of breaking its initial public offering (IPO) price [1] - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 20, 2022, with an initial public offering of 24,174,035 shares at a price of 72.69 yuan per share [1] - On its first day of trading, the stock reached a peak price of 188.00 yuan, which remains the highest point since its listing [1] Group 2 - The total amount raised from the IPO was 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising amount exceeded the originally planned amount by 1,108.17 million yuan, with the initial target set at 513.28 million yuan for projects including "pharmaceutical intermediates, raw materials, and R&D center expansion" as well as "supplementing working capital" [1] - The total issuance costs for the IPO were 135.76 million yuan, with underwriting fees amounting to 117.93 million yuan [2] Group 3 - The actual controllers of Chengda Pharmaceutical are Ge Jianli, Lu Gang, and Lu Jin, with Lu Jin being a Chinese national who holds permanent residency in Canada [3] - On July 3, 2023, the company announced its 2022 annual equity distribution plan, which involves a cash distribution of 3.00 yuan for every 10 shares and a capital reserve increase of 6.00 shares for every 10 shares [3] - The record date for the equity distribution was set for July 6, 2023, with the ex-dividend date on July 7, 2023 [3]

每经AI快讯，博腾股份1月22日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润8000万元 ~1.05亿元，同比扭亏为盈。业绩变动主要原因是，2025年度，公司坚定围绕"收入重新恢复增长，逐步 实现扭亏为盈"的重要经营目标，持续加强业务拓展，提升经营大盘系统管理水平；2025年度，公司预 计实现营业收入33.5-35亿元，同比增长11%~16%，收入增长主要由临床三期至商业化阶段的项目需求 增长驱动。 每经头条（nbdtoutiao）——特朗普强要格陵兰岛，丹麦一养老基金率先清仓美债，美国资产全线下 跌！欧洲手握"金融核按钮"，双方会"鱼死网破"吗？专家解读→ （记者 王晓波） ...